111 related articles for article (PubMed ID: 1915428)
1. Dose-related antiarrhythmic effects of nicainoprol in patients with chronic ventricular arrhythmias--a double-blind, placebo-controlled, cross-over multicentre trial. Nicainoprol Study Group.
Schneider W; Reifart N; Blaeser A; Ostrowski J; Kaltenbach M; Kober G
Eur Heart J; 1991 Aug; 12(8):900-8. PubMed ID: 1915428
[TBL] [Abstract][Full Text] [Related]
2. [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study].
Lardoux H; Maison Blanche P; Marchand X; Canler A; Rouesnel P; Bleinc D; Péraudeau P; Scheck F
Ann Cardiol Angeiol (Paris); 1996 Oct; 45(8):469-79. PubMed ID: 8952741
[TBL] [Abstract][Full Text] [Related]
3. [Dose-related effect of nicainoprol (CAS 924) on basic electrophysiologic parameters in patients with and without diseases of the heart conduction system].
Sen S; Rettig G; Schieffer H; Bette L
Z Kardiol; 1988 Sep; 77(9):600-7. PubMed ID: 3195179
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of mexiletine in chronic ventricular arrhythmias: a multicentre double-blind medium-term trial.
Poggesi L; Scarti L; Ieri A; Lanzetta T; Grazzini M; Del Bene P; Masini G; Del Citerna F; Carnovali M; Masotti G
Int J Clin Pharmacol Res; 1989; 9(4):269-75. PubMed ID: 2476406
[TBL] [Abstract][Full Text] [Related]
5. The antiarrhythmic properties of quifenadine, H1-histamine receptor blocker in children with premature beats: a randomized controlled pilot trial.
Makarov L; Balykova L; Soldatova O; Komolyatova V; Serebruany V
Am J Ther; 2010; 17(4):396-401. PubMed ID: 19487925
[TBL] [Abstract][Full Text] [Related]
6. [Propafenone and flecainide in the therapy of ventricular arrhythmias].
Paperini L; Davini A; Lattanzi F; Topi A; Reisenhofer B; Squarcini G; Paci A; Topi PL
Minerva Cardioangiol; 1995 Oct; 43(10):449-57. PubMed ID: 8819814
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of the efficacy/tolerability ratio of cibenzoline and propafenone in the treatment of ventricular arrhythmia].
Babuty D; Cosnay P; Rouesnel P; Bine-Scheck F; Arnaud R; Fauchier JP
Ann Cardiol Angeiol (Paris); 1992 Apr; 41(4):225-34. PubMed ID: 1642441
[TBL] [Abstract][Full Text] [Related]
8. Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Multicenter Ketanserin Research Group.
Zehender M; Meinertz T; Hohnloser S; Geibel A; Hartung J; Seiler KU; Just H
Clin Physiol Biochem; 1990; 8 Suppl 3():90-100. PubMed ID: 2132179
[TBL] [Abstract][Full Text] [Related]
9. Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure.
Behling A; Moraes RS; Rohde LE; Ferlin EL; Nóbrega AC; Ribeiro JP
Am Heart J; 2003 Sep; 146(3):494-500. PubMed ID: 12947369
[TBL] [Abstract][Full Text] [Related]
10. [Anti-arrhythmic effect of oral propafenone. Apropos of 70 cases].
Coumel P; Leclercq JF; Assayag P; Maisonblanche P; Cauchemez B
Arch Mal Coeur Vaiss; 1984 Nov; 77(12):1370-82. PubMed ID: 6439161
[TBL] [Abstract][Full Text] [Related]
11. Cibenzoline for symptomatic ventricular arrhythmias: a prospective, randomized, double-blind, placebo controlled trial and a long term open label study.
Lee MA; Fenster PE; Garcia ZM; Kipps JE; Huang SK
Can J Cardiol; 1989 Sep; 5(6):295-8. PubMed ID: 2477130
[TBL] [Abstract][Full Text] [Related]
12. Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial.
Saul JP; Scott WA; Brown S; Marantz P; Acevedo V; Etheridge SP; Perry JC; Triedman JK; Burriss SW; Cargo P; Graepel J; Koskelo EK; Wang R;
Circulation; 2005 Nov; 112(22):3470-7. PubMed ID: 16316969
[TBL] [Abstract][Full Text] [Related]
13. [Brazilian multicenter study of sotalol effectiveness in ventricular arrhythmias].
Maia IG; Lorga AM; de Paola AA; Rassi A; Perez AK; Sobral D; Atie J; Gizzi JC; Darwich R
Arq Bras Cardiol; 1996 Mar; 66(3):173-8. PubMed ID: 8762699
[TBL] [Abstract][Full Text] [Related]
14. [Antiarrhythmic drug effectiveness. Proposal for a new approach based on pharmacological hourly effects].
Maia IG; Seixas TN; Costa AM; Perez AK; Alves PA
Arq Bras Cardiol; 1995 Jun; 64(6):525-31. PubMed ID: 8561671
[TBL] [Abstract][Full Text] [Related]
15. [Diprafenone--comparative study of anti-arrhythmia therapy with propafenone].
Geibel A; Zehender M; Hohnloser S; Landsrath C; Meinertz T; Just H
Z Kardiol; 1988 Jul; 77(7):464-9. PubMed ID: 2463720
[TBL] [Abstract][Full Text] [Related]
16. [Therapy of ventricular arrhythmias with propafenone].
Petri H; Kafka W; Rudolph W
Herz; 1985 Feb; 10(1):44-52. PubMed ID: 2579879
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the antiarrhythmic activity of mexiletine and lorcainide on ventricular arrhythmias.
Meinertz T; Kasper W; Stengel E; Waldecker B; Löllgen H; Jähnchen E; Bechtold H; Just J
Z Kardiol; 1982 Jan; 71(1):35-8. PubMed ID: 7039160
[TBL] [Abstract][Full Text] [Related]
18. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
19. [Double-blind randomized placebo-controlled study of the effects of slow release and immediate release forms of propafenone in patients ventricular extrasystole symptoms].
Mastropasqua F; Totaro P; Massari F; Pitzalis MV; Rizzon P
Cardiologia; 1998 Jun; 43(6):617-23. PubMed ID: 9675961
[TBL] [Abstract][Full Text] [Related]
20. Carbon monoxide exposure of subjects with documented cardiac arrhythmias.
Chaitman BR; Dahms TE; Byers S; Carroll LW; Younis LT; Wiens RD
Res Rep Health Eff Inst; 1992 Sep; (52):1-26; discussion 27-37. PubMed ID: 1418771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
